Anemia in Hodgkin's lymphoma: The role of interleukin-6 and hepcidin

Journal of Clinical Oncology

Volumn 28, Issue 15, 2010, Pages 2538-2543

  Hohaus, Stefan ^a   Massini, Giuseppina ^a   Giachelia, Manuela ^a   Vannata, Barbara ^a   Bozzoli, Valentina ^a   Cuccaro, Annarosa ^a   D'Alo', Francesco ^a   Larocca, Luigi Maria ^a   Raymakers, Reinier A P ^a   Swinkels, Dorine W ^a   Voso, Maria Teresa ^a   Leone, Giuseppe ^a  

^a NONE

Author keywords

[No Author keywords available]

Indexed keywords

FIBRINOGEN; HEMOGLOBIN; HEPCIDIN; INTERLEUKIN 10; INTERLEUKIN 6; THYMUS AND ACTIVATION REGULATED CHEMOKINE; ANTIMICROBIAL CATIONIC PEPTIDE; AUTACOID; CCL17 PROTEIN, HUMAN; FERRITIN; IRON;

ACUTE PHASE RESPONSE; ADOLESCENT; ADULT; AGED; ANEMIA; ARTICLE; CONTROLLED STUDY; CORRELATION ANALYSIS; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; HEMOGLOBIN BLOOD LEVEL; HODGKIN DISEASE; HUMAN; ION EXCHANGE CHROMATOGRAPHY; IRON BINDING CAPACITY; IRON METABOLISM; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; TIME OF FLIGHT MASS SPECTROMETRY; BLOOD; CASE CONTROL STUDY; MASS SPECTROMETRY; METABOLISM; MIDDLE AGED;

ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; ANEMIA; ANTIMICROBIAL CATIONIC PEPTIDES; CASE-CONTROL STUDIES; CHEMOKINE CCL17; ENZYME-LINKED IMMUNOSORBENT ASSAY; FEMALE; FERRITINS; HODGKIN DISEASE; HUMANS; INFLAMMATION MEDIATORS; INTERLEUKIN-10; INTERLEUKIN-6; IRON; MALE; MASS SPECTROMETRY; MIDDLE AGED; YOUNG ADULT;

EID: 77956401198     PISSN: 0732183X     EISSN: 15277755     Source Type: Journal    
DOI: 10.1200/JCO.2009.27.6873     Document Type: Article

References (42)

1. Keel SB, Abkowitz JL: The microcytic red cell and the anemia of inflammation. N Engl J Med 361:1904-1906, 2009
2. Weiss G, Goodnough LT: Anemia of chronic disease. N Engl J Med 352:1011-1023, 2005
3. Bezwoda WR, Derman DP, Bothwell TH, et al: Serum ferritin and Hodgkin's disease. Scand J Haematol 35:505-510, 1985 (Pubitemid 16156008)
4. Dörner MH, Abel U, Fritze D, et al: Serum ferritin in relation to the course of Hodgkin's disease. Cancer 52:2308-2312, 1983 (Pubitemid 14205955)
5. Means RT: Hepcidin and cytokines in anaemia. Hematology 9:357-362, 2004
6. Ganz T: Hepcidin, a key regulator of iron metabolism and mediator of anemia of inflammation. Blood 102:783-788, 2003
7. Ganz T: Hepcidin and its role in regulating systemic iron metabolism. Hematology Am Soc Hematol Educ Program 2006:29-35, 507
8. Nemeth E, Ganz T: Hepcidin and iron-loading anemias. Haematologica 91:727-732, 2006 (Pubitemid 44014536)
9. Camaschella C, Silvestri L: New and old players in the hepcidin pathway. Haematologica 93: 1441-1444, 2008
10. Ganz T, Nemeth E: Iron sequestration and anemia of inflammation. Semin Hematol 46:387-393, 2009
11. Kemna EH, Tjalsma H, Willems HL, et al: Hepcidin: From discovery to differential diagnosis. Haematologica 93:90-97, 2008 (Pubitemid 351156156)
12. Nemeth E, Rivera S, Gabayan V, et al: IL-6 mediates hypoferremia of inflammation by inducing the synthesis of the iron regulatory hormone hepcidin. J Clin Invest 113:1271-1276, 2004 (Pubitemid 39069926)
13. Kemna E, Pickkers P, Nemeth E, et al: Time-course analysis of hepcidin, serum iron, and plasma cytokine levels in humans injected with LPS. Blood 106:1864-1866, 2005
14. Weiss G: Iron metabolism in the anemia of chronic disease. Biochim Biophys Acta 1790:682-693, 2009
15. Wrighting DM, Andrews NC: Interleukin-6 induces hepcidin expression through STAT3. Blood 108:3204-3209, 2006
16. Verga Falzacappa MV, Vujic Spasic M, Kessler R, et al: STAT3 mediates hepatic hepcidin expression and its inflammatory stimulation. Blood 109:353-358, 2007 (Pubitemid 46053077)
17. Pietrangelo A, Dierssen U, Valli L, et al: STAT3 is required for IL-6-gp130-dependent activation of hepcidin in vivo. Gastroenterology 132:294-300, 2007 (Pubitemid 46108739)
18. Peyssonnaux C, Zinkernagel AS, Datta V, et al: TLR4-dependent hepcidin expression by myeloid cells in response to bacterial pathogens. Blood 107:3727-3732, 2006
19. Skinnider BF, Mak TW: The role of cytokines in classical Hodgkin lymphoma. Blood 99:4283-4297, 2002 (Pubitemid 34627193)
20. Casasnovas RO, Mounier N, Brice P, et al: Plasma cytokine and soluble receptor signature predicts outcome of patients with classical Hodgkin's lymphoma: A study from the Groupe d'Etude des Lymphomes de l'Adulte. J Clin Oncol 25:1732-1740, 2007 (Pubitemid 46797954)
21. Hohaus S, Giachelia M, Massini G, et al: Clinical significance of interleukin-10 gene polymorphisms and plasma levels in Hodgkin lymphoma. Leuk Res 33:1352-1356, 2009
22. Niens M, Visser L, Nolte IM, et al: Serum chemokine levels in Hodgkin lymphoma patients: Highly increased levels of CCL17 and CCL22. Br J Haematol 140:527-536, 2008 (Pubitemid 351230079)
23. Hasenclever D, Diehl V: A prognostic score for advanced Hodgkin's disease. N Engl J Med 339:1506-1514, 1998 (Pubitemid 28543499)
24. Kroot JJ, Hendriks JC, Laarakkers CM, et al: (Pre)analytical imprecision, between-subject variability, and daily variations in serum and urine hepcidin: Implications for clinical studies. Anal Biochem 389:124-129, 2009
25. Swinkels DW, Girelli D, Laarakkers C, et al: Advances in quantitative hepcidin measurements by time-of-flight mass spectrometry. PLoS One 3:e2706, 2008
26. Peters HP, Laarakkers CM, Swinkels DW, et al: Serum hepcidin-25 levels in patients with chronic kidney disease are independent of glomerular filtration rate. Nephrol Dial Transplant 25:848-853, 2010
27. Lou DQ, Lesbordes JC, Nicolas G, et al: Ironand inflammation-induced hepcidin gene expression in mice is not mediated by Kupffer cells in vivo. Hepatology 41:1056-1064, 2005 (Pubitemid 40593913)
28. Macciò A, Madeddu C, Massa D, et al: Hemoglobin levels correlate with interleukin-6 levels in patients with advanced untreated epithelial ovarian cancer: Role of inflammation in cancer-related anemia. Blood 106:362-367, 2005 (Pubitemid 40967214)
29. Sharma S, Nemeth E, Chen YH, et al: Involvement of hepcidin in the anemia of multiple myeloma. Clin Cancer Res 14:3262-3267, 2008
30. Lee P, Peng H, Gelbart T, et al: Regulation of hepcidin transcription by interleukin-1 and interleukin-6. Proc Natl Acad Sci U S A 102:1906-1910, 2005
31. van Deuren M, Kroot JJ, Swinkels DW: Time-course analysis of serum hepcidin, iron and cytokines in a C282Y homozygous patient with Schnitzler's syndrome treated with IL-1 receptor antagonist. Haematologica 94:1297-1300, 2009
32. Nemeth E, Valore EV, Territo M, et al: Hepcidin, a putative mediator of anemia of inflammation, is a type II acute-phase protein. Blood 101:2461-2463, 2003 (Pubitemid 36857598)
33. van Gameren MM, Willemse PH, Mulder NH, et al: Effects of recombinant human interleukin-6 in cancer patients: A phase I-II study. Blood 84:1434-1441, 1994
34. Atkins MB, Kappler K, Mier JW, et al: Interleukin-6-associated anemia: Determination of the underlying mechanism. Blood 86:1288-1291, 1995
35. Ogawa M: Differentiation and proliferation of hematopoietic stem cells. Blood 81:2844-2853, 1993
36. Goicoechea M, Martin J, de Sequera P, et al: Role of cytokines in the response to erythropoietin in hemodialysis patients. Kidney Int 54:1337-1343, 1998 (Pubitemid 28449924)
37. Graziadei I, Gaggl S, Kaserbacher R, et al: The acute-phase protein alpha 1-antitrypsin inhibits growth and proliferation of human early erythroid progenitor cells (burst-forming units-erythroid) and of human erythroleukemic cells (K562) in vitro by interfering with transferrin iron uptake. Blood 83: 260-268, 1994
38. Feelders RA, Vreugdenhil G, van Dijk JP, et al: Decreased affinity and number of transferrin receptors on erythroblasts in the anemia of rheumatoid arthritis. Am J Hematol 43:200-204, 1993 (Pubitemid 23164784)
39. Ukarma L, Johannes H, Beyer U, et al: Hepcidin as a predictor of response to epoetin therapy in anemic cancer patients. Clin Chem 55:1354-1360, 2009
40. Vener C, Guffanti A, Pomati M, et al: Soluble cytokine levels correlate with the activity and clinical stage of Hodgkin's disease at diagnosis. Leuk Lymphoma 37:333-339, 2000 (Pubitemid 30162543)
41. Biggar RJ, Johansen JS, Smedby KE, et al: Serum YKL-40 and interleukin 6 levels in Hodgkin lymphoma. Clin Cancer Res 14:6974-6978, 2008
42. Kawabata H, Tomosugi N, Kanda J, et al: Anti-interleukin 6 receptor antibody tocilizumab reduces the level of serum hepcidin in patients with multicentric Castleman's disease. Haematologica 92:857-858, 2007 (Pubitemid 350155317)